Piper Jaffray & Co.



Piper Jaffray & Co. Recent News

UPDATE: Piper Jaffray Reiterates Overweight Rating, Raises PT on Cree
UPDATE: Piper Jaffray Reiterates Neutral Rating, Raises PT on Polycom
UPDATE: Piper Jaffray Reiterates Overweight Rating, Lowers PT on McGraw-Hill Companies
UPDATE: Piper Jaffray Reiterates Overweight Rating, Raises PT on Moody's Corporation
UPDATE: Piper Jaffray Reiterates Overweight Rating, Lowers PT on Moneygram International
Piper Jaffray Reiterates Neutral Rating, $13 PT on Best Buy
UPDATE: Piper Jaffray Reiterates Neutral Rating, Raises PT on Alliance Data Systems Corporation
UPDATE: Piper Jaffray Reiterates Neutral Rating, Lowers PT on Tilly's
UPDATE: Piper Jaffray Reiterates Neutral Rating, Lowers PT on Pacific Sunwear of California
UPDATE: Piper Jaffray Reiterates Neutral Rating, Lowers PT on Deckers Outdoor Corp.
UPDATE: Piper Jaffray Downgrades Aeropostale to Neutral, Lowers PT
UPDATE: Piper Jaffray Reiterates Overweight Rating, Raises PT on HSN
UPDATE: Piper Jaffray Reiterates Neutral Rating, Raises PT on Apollo Group
Piper Jaffray Reiterates Overweight Rating, $100 PT on athenahealth
UPDATE: Piper Jaffray Reiterates Neutral Rating, Raises PT on Sequenom
UPDATE: Piper Jaffray Reiterates Neutral Rating, Lowers PT on Synageva BioPharma Corp.
UPDATE: Piper Jaffray Downgrades Endo Health Solutions to Neutral, Lowers PT
UPDATE: Piper Jaffray Initiates Coverage on Cytokinetics with Overweight Rating, $4 PT
UPDATE: Piper Jaffray Downgrades Cepheid to Neutral, Lowers PT
UPDATE: Piper Jaffray Initiates Coverage on BioDelivery Sciences International with Neutral Rating, $5 PT
UPDATE: Piper Jaffray Initiates Coverage on Avanir Pharmaceuticals with Overweight Rating, $6 PT
UPDATE: Piper Jaffray Initiates Coverage on Alexza Pharmaceuticals to Neutral Rating, $5 PT
Piper Jaffray Reiterates Overweight Rating, $103 PT on Watson Pharmaceuticals